Unknown

Dataset Information

0

Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses.


ABSTRACT: The limited efficacy of existing antiviral therapies for influenza--coupled with widespread baseline antiviral resistance--highlights the urgent need for more effective therapy. We describe a triple combination antiviral drug (TCAD) regimen composed of amantadine, oseltamivir, and ribavirin that is highly efficacious at reducing mortality and weight loss in mouse models of influenza infection. TCAD therapy was superior to dual and single drug regimens in mice infected with drug-susceptible, low pathogenic A/H5N1 (A/Duck/MN/1525/81) and amantadine-resistant 2009 A/H1N1 influenza (A/California/04/09). Treatment with TCAD afforded >90% survival in mice infected with both viruses, whereas treatment with dual and single drug regimens resulted in 0% to 60% survival. Importantly, amantadine had no activity as monotherapy against the amantadine-resistant virus, but demonstrated dose-dependent protection in combination with oseltamivir and ribavirin, indicative that amantadine's activity had been restored in the context of TCAD therapy. Furthermore, TCAD therapy provided survival benefit when treatment was delayed until 72 hours post-infection, whereas oseltamivir monotherapy was not protective after 24 hours post-infection. These findings demonstrate in vivo efficacy of TCAD therapy and confirm previous reports of the synergy and broad spectrum activity of TCAD therapy against susceptible and resistant influenza strains in vitro.

SUBMITTER: Nguyen JT 

PROVIDER: S-EPMC3264642 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses.

Nguyen Jack T JT   Smee Donald F DF   Barnard Dale L DL   Julander Justin G JG   Gross Matthew M   de Jong Menno D MD   Went Gregory T GT  

PloS one 20120123 1


The limited efficacy of existing antiviral therapies for influenza--coupled with widespread baseline antiviral resistance--highlights the urgent need for more effective therapy. We describe a triple combination antiviral drug (TCAD) regimen composed of amantadine, oseltamivir, and ribavirin that is highly efficacious at reducing mortality and weight loss in mouse models of influenza infection. TCAD therapy was superior to dual and single drug regimens in mice infected with drug-susceptible, low  ...[more]

Similar Datasets

| S-EPMC2727327 | biostudies-literature
| S-EPMC2849588 | biostudies-literature
| S-EPMC6496959 | biostudies-literature
| S-EPMC3912210 | biostudies-literature
| S-EPMC3248427 | biostudies-literature
| S-EPMC2825274 | biostudies-literature
| S-EPMC3579783 | biostudies-literature
| S-EPMC5777222 | biostudies-literature
| S-EPMC4807618 | biostudies-literature
| S-EPMC2657637 | biostudies-literature